Burning Rock Biotech (BNR) Common Equity: 2019-2024
- Burning Rock Biotech's Common Equity fell 26.48% to $79.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $79.6 million, marking a year-over-year decrease of 26.48%. This contributed to the annual value of $79.6 million for FY2024, which is 26.48% down from last year.
- Latest data reveals that Burning Rock Biotech reported Common Equity of $79.6 million as of Q4 2024, which was down 26.48% from $108.2 million recorded in Q4 2023.
- Burning Rock Biotech's 5-year Common Equity high stood at $371.0 million for Q4 2020, and its period low was $79.6 million during Q4 2024.
- Over the past 3 years, Burning Rock Biotech's median Common Equity value was $108.2 million (recorded in 2023), while the average stood at $118.6 million.
- As far as peak fluctuations go, Burning Rock Biotech's Common Equity surged by 393.34% in 2020, and later slumped by 42.00% in 2022.
- Over the past 5 years, Burning Rock Biotech's Common Equity (Quarterly) stood at $371.0 million in 2020, then declined by 21.96% to $289.6 million in 2021, then slumped by 42.00% to $167.9 million in 2022, then tumbled by 35.56% to $108.2 million in 2023, then declined by 26.48% to $79.6 million in 2024.
- Its Common Equity stands at $79.6 million for Q4 2024, versus $108.2 million for Q4 2023 and $167.9 million for Q4 2022.
